Welcome to our dedicated page for Endra Life Sciences news (Ticker: NDRA), a resource for investors and traders seeking the latest updates and insights on Endra Life Sciences stock.
ENDRA Life Sciences Inc. reports developments in thermoacoustic biomarker imaging, including its TAEUS® Liver device for measuring liver fat in steatotic liver disease, MASLD and MASH. Company news commonly covers clinical feasibility work comparing TAEUS measurements with MRI-PDFF, device repeatability and reproducibility, and business updates tied to operating results.
NDRA updates also include capital and treasury actions, such as private placement financing and a digital asset treasury strategy involving HYPE token holdings and staking. Corporate news has included strategic-review announcements and Nasdaq listing-compliance matters.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) announced its participation in the H.C. Wainwright 22nd Annual Virtual Global Investment Conference on September 16, 2020, at 11 a.m. ET. Management will present the company's innovative Thermo Acoustic Enhanced UltraSound (TAEUS) technology, which visualizes tissue at a fraction of the cost of traditional imaging methods. The conference runs from September 14-16, and one-on-one investor meetings can be arranged. The presentation will be available for livestreaming and replay via the company's website.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) announced its participation in the LD 500 Virtual Investor Conference from September 1-4, 2020. The company will present on September 3, 2020, at 2:00 PM ET. CEO Francois Michelon will lead the presentation, which includes one-on-one meetings. ENDRA focuses on Thermo Acoustic Enhanced Ultrasound (TAEUS), an innovative technology for assessing liver conditions like NAFLD and NASH, aiming to provide cost-effective diagnostics. For details, visit their webcast.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) is showcasing its Thermo Acoustic Enhanced UltraSound (TAEUS®) technology at the Digital International Liver Congress (ILC) from August 27-29, 2020. This virtual event allows ENDRA to enhance brand awareness and commercial strategies by exhibiting its TAEUS Fatty Liver Imaging Probe (FLIP) System. Following the CE Mark obtained earlier this year, ENDRA focuses on establishing clinical evaluation sites in Europe and has submitted a 510(k) application to the U.S. FDA for TAEUS FLIP, which is currently under review.
ENDRA Life Sciences (NASDAQ: NDRA) announced the early exercise of about 7.1 million common stock warrants, generating approximately $5 million in gross proceeds. Since July 1, 2020, this early exercise by significant shareholders is viewed as a vote of confidence in ENDRA's developments, including CE Mark approval in Europe and the submission for FDA clearance of its TAEUS FLIP system. The funds are expected to extend the company's cash runway for establishing evaluation sites and initiating sales in Europe, with hopes for U.S. commercialization this year.